Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Affiliations

• ¹ Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
• ² Department of Pediatric Hematology and Oncology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey.
• ³ Università di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.
• ⁴ Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
• ⁵ First Department of Pediatrics, University of Athens, Athens, Greece.
• ⁶ Campus of Haematology Franco e Piera Cutino Azienda Ospedaliera Ospedali Riuniti Villa Sofia V. Cervello, Palermo, Italy.
• ⁷ Department of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
• ⁸ Novartis Pharma AG, Basel, Switzerland.
• ⁹ Novartis Pharma S.A.S., Rueil Malmaison, France.
• ¹⁰ Novartis Pharmaceuticals Corporation, East Hanover, NJ; and.
• ¹¹ Ege University Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey.